Does an enhanced recovery after surgery protocol change costs and outcomes of single-level lumbar microdiscectomy?

Ebru Tarkan Kılcı, MD,1 Tuncay Demirbilek, MD,2 and Sait Naderi, MD2

Departments of 1Anesthesiology and Perioperative Medicine and 2Neurosurgery, Ümraniye Training and Research Hospital, Ümraniye, İstanbul, Turkey

OBJECTIVE Enhanced recovery after surgery (ERAS) is a multimodal approach that aims to improve perioperative surgical outcomes. The aim of this study was to evaluate the benefits of ERAS in terms of cost-effectiveness and postoperative outcomes in single-level lumbar microdiscectomy.

METHODS This study was a single-center retrospective comparing costs and outcomes before and after implementation of the ERAS pathway. Data were collected from the electronic medical records of patients who had undergone single-level lumbar microdiscectomy during 2 time periods—during the 2 years preceding implementation of the ERAS pathway (pre-ERAS group) and after implementation of the ERAS pathway (ERAS group). Each group consisted of 60 patients with an American Society of Anesthesiologists (ASA) Physical Status Classification of class 1. Patients were excluded if their physical status was classified as ASA class II–V or if they were younger than 18 years or older than 65.

Groups were compared in terms of age, sex, body mass index (BMI), perioperative hemodynamics, operation time, intraoperative blood loss, intraoperative fluid administration, intraoperative opioid administration, time to first oral intake, time to first mobilization, postoperative nausea and vomiting (PONV), difference between preoperative and postoperative visual analog scale (VAS) scores, postoperative analgesic requirements, length of hospital stay, and cost of anesthesia.

RESULTS The ERAS and pre-ERAS groups were comparable with respect to age, sex, and BMI. Operation time, intraoperative blood loss, intraoperative opioid administration, and intraoperative fluid administration were all less in the ERAS group. First oral intake and first mobilization were earlier in the ERAS group. The incidence of PONV was less in the ERAS group. Postoperative analgesic requirements and postoperative VAS scores were significantly less in the ERAS group. The length of hospital stay was found to be shorter in the ERAS group. The ERAS approach was found to be cost-effective.

CONCLUSIONS ERAS had clinical and economic benefits and is associated with improved outcomes in lumbar microdiscectomy.

https://thejns.org/doi/abs/10.3171/2019.1.FOCUS18665

KEYWORDS enhanced recovery after surgery; ERAS; lumbar microdiscectomy; cost-effective; economics

ABBREVIATIONS ASA = American Society of Anesthesiologists; BMI = body mass index; DBP = diastolic blood pressure; ERAS = enhanced recovery after surgery; HR = heart rate; PACU = post-anesthetic care unit; PONV = postoperative nausea and vomiting; SBP = systolic blood pressure; SPO2 = peripheral oxygen saturation; TIVA = total intravenous anesthesia; TL = Turkish Liras; VAS = visual analog scale.


INCLUDE WHEN CITING DOI: 10.3171/2019.1.FOCUS18665.

©AANS 2019, except where prohibited by US copyright law
tical specialties including spine surgery. Spine surgery has lagged behind several other subspecialties in adopting ERAS protocols.

There are still several barriers, including cultural concerns, conventional attitudes, and institutional resistance to change or lack of experience of the surgeons regarding this new approach. Due to the heterogeneity of pathology, variations in the extent of the surgical stress response, and multiple different options for surgical and anesthetic approaches, no unique ERAS pathway has been defined for all spine surgeries.

Although a large number of clinical studies have confirmed the benefits of an ERAS program, the feasibility and effectiveness in the setting of spine surgery are still unknown.

Therefore we aimed to compare the cost-effectiveness and surgical outcomes of single-level lumbar microdiscectomy before and after we instituted an ERAS pathway.

Methods

Study Designs

This was a retrospective study, involving 120 patients with American Society of Anesthesiologists (ASA) Physical Status Classification of class 1, who underwent single-level lumbar microdiscectomy. Data were collected by manual review of the electronic medical record. All procedures were performed in strict accordance with the principles set by the Declaration of Helsinki.

The records of 60 patients who had undergone surgery who were treated just after ERAS implementation (ERAS group) and 60 patients who were treated in the 2 years preceding ERAS implementation (the last 60 treated during that period, pre-ERAS group) were compared in terms of age, sex, body mass index (BMI), perioperative hemodynamics, operation time, intraoperative blood loss, intraoperative fluid administration, intraoperative opioid administration, time to first oral intake, time to first mobilization, postoperative nausea and vomiting (PONV), preoperative-postoperative visual analog scale (VAS) pain scores, postoperative analgesic requirements, length of hospital stay, and cost of anesthesia.

Pre-ERAS Group

Patients were admitted the day before the operation. The perioperative care and preoperative counseling depended on the surgeon’s preference. Prophylactic antibiotic treatment was administered 30 minutes before the patient was taken to the operating room. Thromboembolism prophylaxis and antiemetic prophylaxis were not used. Fasting time for clear fluid was 4 hours and that for solids was 8 hours.

Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and peripheral oxygen saturation (SpO2) were monitored throughout the procedure. The time points of these indexes were recorded before induction of anesthesia, after the induction of anesthesia, at 30 minutes into the surgery, and after the completion of the surgery.

General anesthesia was induced using fentanyl 2–4 μg/kg, propofol 2 mg/kg, vecuronium 0.6–0.8 mg/kg, and midazolam 0.1–0.2 mg/kg. After tracheal intubation, the patients were placed in the prone position on the operating table and then anesthesia was maintained via inhalation of 2% sevoflurane 50%:50% oxygen/nitrous oxide. Convective warming was not used. When the breathing pattern was restored the patient was extubated and transferred to the post-anesthetic care unit (PACU). The operation time and total blood loss were recorded. The standard intravenous fluid administration rate was set at 2.5 L/24 hours. In case of hypotension bolus fluid resuscitation was used. Postoperative oral intake was prohibited. For postoperative pain management intravenous meperidine or morphine substitutes were used. Local infiltrative analgesia into the subcutaneous tissues after closure was not used. Nasogastric tubes or urinary catheters were not used. Patients were discharged when they were able to start daily activities and otherwise ready for discharge.

ERAS Group

Patients were admitted the day before the operation. Preoperative counseling was performed by anesthesiologists, surgeons, and nurses about the ERAS program for psychological comfort and education. We engaged support from our hospital to schedule the same anesthesiologists, surgeon, and nurses for the ERAS patients wherever possible. Selection was based on their understanding of and willingness to apply ERAS principles. According to our hospital policy we permitted clear fluids up to 2 hours before surgery and solid foods up to 4 hours before surgery. Perioperative fluid management was restricted to avoid overload.

On the day of the operation all patients received antibiotic prophylaxis 30 minutes before the first incision of the operation in compliance with ERAS guidelines. Thromboembolism prophylaxis with low-molecular-weight heparin (injected subcutaneously) and antiemetic prophylaxis of 0.15 mg/kg ondansetron and 0.2 mg/kg dexamethasone (injected intravenously) were administered preoperatively. The patients’ SBP, DBP, HR, and SpO2 were monitored throughout the surgical procedure and the values were recorded at the following time points: before induction of anesthesia, after induction of anesthesia, at 30 minutes after the beginning of the surgery, and after the completion of the surgery. Total intravenous anesthesia (TIVA) was preferentially induced with fentanyl 1 μg/kg and 2 mg/kg propofol; pure oxygen ventilation (via endotracheal tube) was used during surgery, and anesthesia was maintained using 2–4 mg/kg/hr propofol via intravenous micropump until the operation was completed. Convective warming devices were used to achieve normothermia at 36°C throughout the operation. When the breathing pattern was restored the patient was extubated and transferred to the PACU. The duration of the operation and total amount of blood loss were recorded. Fluid management was limited to 500 ml during surgery to achieve euvolemia for all patients. In case of hypotension, vasopressors were administered. For postoperative pain management, a 30-ml bolus containing 0.5% bupivacaine hydrochloride (Marcaine) was infiltrated into the local subcutaneous tissue after closure and acetaminophen (1000 mg) was administered intravenously. No nasogastric tubes or urinary catheters were utilized. When the patients returned to the regular ward, they were
encouraged to sit out of the bed for mobilization within 2 hours and oral intake was resumed as soon as possible. An opioid-sparing multimodal approach to pain management was adopted. VAS scores were recorded at 6 and 12 hours after surgery. In patient education, it was emphasized that acetaminophen should be used before an opioid analgesic. Tramadol was available for rescue analgesia. Patients were discharged from the hospital when they had satisfactory recovery with respect to activities of daily living and pain control and were otherwise ready for discharge.

**Surgical Technique**

All patients underwent a 1-level microdiscectomy procedure. Patients were positioned prone on a surgical frame in a neutral position. After the patient was positioned, prepped, and draped, C-arm fluoroscopy of the lumbar spine was performed for confirmation of the surgical intervertebral disc level. In the pre-ERAS group, a 2.5-cm skin incision was made, and the fascia was opened in the midline. The skin incision was shorter than 2 cm in the patients in the ERAS group. A 10-mm-diameter Taylor retractor was used for retraction of paravertebral muscles at the level of the herniated disc. The Taylor retractor was docked using navigation guidance to confirm the level of surgery. Once the retractor was docked, a microscope was brought in and used until the removal of the Taylor retractor. In the pre-ERAS group the microdiscectomy procedure was carried out after removal of the ligamentum flavum, whereas in the ERAS group the microdiscectomy procedure was performed using a ligamentum flavum-preserving technique, as described in the literature.

Subcutaneous closure was performed with 2-0 Vicryl suture. In the ERAS group about 30 ml of 0.5% bupivacaine hydrochloride was infiltrated into the subcutaneous tissues after closure, as described above. The skin was reaproximated and was sutured with 3-0 Vicryl in pre-ERAS group patients, and with Dermabond and a Steri-Strip in the ERAS group. No Foley catheters or drains of any sort were utilized.

**Statistical Analysis**

Data were analyzed using NCSS (2007) and the variables are presented as mean ± standard deviation (SD) or number. Age, BMI, and perioperative hemodynamic variables were compared between groups using Student t-test. Continuous data, operation time, intraoperative blood loss, intraoperative fluid administration, and intraoperative opioid requirements were analyzed using Mann-Whitney U-tests, and preoperative-postoperative VAS scores were analyzed using Wilcoxon signed-rank tests. Sex, postoperative analgesic use, and PONV were compared using Pearson chi-square tests. A p value < 0.05 was considered statistically significant.

**Results**

The ERAS group included 60 ASA 1 patients with a mean age of 50.43 ± 6.84 years, and the pre-ERAS group included 60 ASA 1 patients with a mean age of 49.80 ± 6.04 years (p = 0.69). There were no significant differences between the groups in terms of demographic parameters (p > 0.5) (Table 1).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Pts (n = 120)</th>
<th>Pre-ERAS (n = 60)</th>
<th>ERAS (n = 60)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age in yrs</td>
<td>50.12 ± 6.43</td>
<td>49.80 ± 6.04</td>
<td>50.43 ± 6.84</td>
<td>0.691*</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>65 (54.2)</td>
<td>35 (58.3)</td>
<td>30 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>55 (45.8)</td>
<td>25 (41.7)</td>
<td>30 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Mean BMI in kg/m²</td>
<td>28.33 ± 4.63</td>
<td>28.56 ± 5.34</td>
<td>28.09 ± 3.83</td>
<td>0.918*</td>
</tr>
</tbody>
</table>

Pts = patients. Mean values are given with SDs.
* Student t-test.
† Pearson chi-square test.

There was no statistically significant between-groups difference with respect to SBP or DBP before induction of anesthesia, but the SBP and DBP at other time points were significantly lower in the ERAS group (all p < 0.05). The mean operation time was 86.42 ± 18.39 minutes in the pre-ERAS group and 78.50 ± 25.20 minutes in the ERAS group (p = 0.012). The mean blood loss was less in the ERAS group than in the pre-ERAS group (p = 0.001). Intraoperative fluid administration and intraoperative opioid administration were found to be less in the ERAS group (p = 0.001). First postoperative oral intake and first mobilization were significantly earlier in the ERAS group (p = 0.001). First postoperative oral intake and first postoperative mobilization were significantly earlier in the ERAS group (p = 0.001). The incidence of recorded PONV was less in the ERAS group (p = 0.001). Postoperative analgesic requirements were found to be significantly less in the ERAS group (p = 0.001). The length of hospital stay was found to be 30.10 ± 7.80 hours in the pre-ERAS group and 26.52 ± 5.16 hours in the ERAS group (p = 0.001). The cost of anesthesia was found to be 87.16 Turkish Liras (TL) in the pre-ERAS group, but only 73.00 ± 24.93 TL in the ERAS group (p = 0.001). The cost of surgery was found to be 1991.67 ± 67.12 TL in the pre-ERAS group and 1258.67 ± 39.89 TL in the ERAS group (p = 0.001) (Table 3). Postoperative VAS scores were found to be significantly lower in the ERAS group (p = 0.001) (Table 4).
Discussion

The success achieved with the use of ERAS in many surgical specialties suggests that similar benefits can be achieved in spine surgery.9 Our study highlights the positive perioperative outcomes in patients undergoing lumbar microdiscectomy. The key challenge is the ERAS pathway itself, with the operative team’s compliance with the protocols rather than the surgical approach as the main determinant of good outcomes.4

In this paper we provide a first full description of our ERAS protocol tailored for lumbar microdiscectomy and demonstrate its association with short operation time, less blood loss, lower pain scores, shorter length of hospital stay, and lower cost.

Our enhanced recovery program included patient participation education, appropriate antibiotic administration, thromboembolism prophylaxis, opioid-sparing anesthetic management with TIVA, temperature management, fluid limitations, PONV prophylaxis, pain management, and implementation of a minimally invasive surgical technique. In the postoperative period early mobilization and early diet advancements were strongly supported by our ERAS team.

The use of TIVA minimized the stress response, avoid-

### TABLE 2. Vital signs of patients in the pre-ERAS and ERAS groups at different time points

<table>
<thead>
<tr>
<th>Parameter &amp; Group</th>
<th>Before Induction of Anesthesia</th>
<th>After Induction of Anesthesia</th>
<th>30 Mins Into Op</th>
<th>At End of the Op</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-ERAS</td>
<td>141.60 ± 16.30</td>
<td>136.60 ± 15.40</td>
<td>132.20 ± 18.70</td>
<td>117.60 ± 14.50</td>
<td>0.039</td>
</tr>
<tr>
<td>ERAS</td>
<td>140.40 ± 20.90</td>
<td>116.60 ± 25.80</td>
<td>112.80 ± 23.80</td>
<td>135.70 ± 8.50</td>
<td></td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-ERAS</td>
<td>89.10 ± 9.40</td>
<td>83.20 ± 8.70</td>
<td>77.30 ± 10.60</td>
<td>72.40 ± 15.30</td>
<td>0.035</td>
</tr>
<tr>
<td>ERAS</td>
<td>74.20 ± 15.6</td>
<td>64.40 ± 13.60</td>
<td>66.80 ± 7.40</td>
<td>68.80 ± 10.30</td>
<td></td>
</tr>
<tr>
<td>HR (bpm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.670</td>
</tr>
<tr>
<td>Pre-ERAS</td>
<td>74.40 ± 15.50</td>
<td>76.30 ± 17.70</td>
<td>78.40 ± 16.40</td>
<td>73.40 ± 16.70</td>
<td></td>
</tr>
<tr>
<td>ERAS</td>
<td>73.60 ± 18.50</td>
<td>78.50 ± 15.70</td>
<td>75.30 ± 13.10</td>
<td>70.70 ± 19.90</td>
<td></td>
</tr>
<tr>
<td>$\text{SpO}_2$ (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.917</td>
</tr>
<tr>
<td>Pre-ERAS</td>
<td>92.50 ± 4.10</td>
<td>93.40 ± 4.90</td>
<td>93.70 ± 4.80</td>
<td>93.80 ± 4.10</td>
<td></td>
</tr>
<tr>
<td>ERAS</td>
<td>92.60 ± 3.80</td>
<td>92.90 ± 8.20</td>
<td>93.30 ± 3.50</td>
<td>93.80 ± 7.60</td>
<td></td>
</tr>
</tbody>
</table>

* Student t-test.

### TABLE 3. Intraoperative and postoperative outcomes

<table>
<thead>
<tr>
<th>Variable</th>
<th>All Pts (n = 120)</th>
<th>Pre-ERAS (n = 60)</th>
<th>ERAS (n = 60)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Op time in mins</td>
<td>82.46 ± 22.32</td>
<td>86.42 ± 18.39</td>
<td>78.50 ± 25.20</td>
<td>0.012†</td>
</tr>
<tr>
<td>Intraop blood loss in ml</td>
<td>140.4 ± 67.44</td>
<td>187.67 ± 47.37</td>
<td>93.17 ± 48.89</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Intraop fluid admin in ml</td>
<td>1354.5 ± 765.79</td>
<td>2044.1 ± 401.38</td>
<td>665.0 ± 233.49</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Intraop opioid admin in μg</td>
<td>98.96 ± 51.69</td>
<td>147.92 ± 22.69</td>
<td>50</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Time to 1st oral intake in hrs</td>
<td>3.89 ± 1.42</td>
<td>4.90 ± 1.08</td>
<td>2.88 ± 0.92</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Time to 1st mobilization in hrs</td>
<td>5.65 ± 2.36</td>
<td>7.20 ± 2.33</td>
<td>4.10 ± 0.95</td>
<td>0.001**†</td>
</tr>
<tr>
<td>PONV, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.001***‡</td>
</tr>
<tr>
<td>No</td>
<td>73 (60.8)</td>
<td>22 (36.7)</td>
<td>51 (85.0)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>47 (39.2)</td>
<td>38 (63.3)</td>
<td>9 (15.0)</td>
<td></td>
</tr>
<tr>
<td>Postop analgesic required, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.001**‡</td>
</tr>
<tr>
<td>No</td>
<td>52 (43.3)</td>
<td>0 (0)</td>
<td>52 (86.7)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>68 (56.7)</td>
<td>60 (100)</td>
<td>8 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Length of hospital stay in hrs</td>
<td>28.31 ± 6.83</td>
<td>30.10 ± 7.80</td>
<td>26.52 ± 5.16</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Cost of anesthesia in TL</td>
<td>171.7 ± 117.9</td>
<td>270.42 ± 87.16</td>
<td>73.00 ± 24.93</td>
<td>0.001**†</td>
</tr>
<tr>
<td>Cost of op in TL</td>
<td>1625.17 ± 372.12</td>
<td>1991.67 ± 67.12</td>
<td>1258.67 ± 39.89</td>
<td>0.001**†</td>
</tr>
</tbody>
</table>

Admin = administration; PONV = postoperative nausea and vomiting; TL = Turkish Liras.
Data are presented as mean ± SD unless otherwise indicated.
* p < 0.05.
** p < 0.01.
† Mann-Whitney U-test.
‡ Pearson chi-square test.
ing the consistent inhalation/opioid-based anesthetic regimen. Selecting techniques with a view to reducing the physiological response to surgery is one of the ERAS goals, and administering any sedation agent can result in undesirable effects.11,12 Additionally, TIVA—with its ease of titration—lowers the risk of airway problems, while facilitating appropriate surgical conditions. Determining the best mode of general anesthesia or regional anesthesia requires additional study of ERAS protocols for spine surgery.1

Bupivacaine hydrochloride was used for local infiltration analgesia. Cost-benefit analysis supported its use. Many studies have demonstrated bupivacaine’s benefits in reducing postoperative pain, similar to our findings. Moreover, routine use of bupivacaine hydrochloride may be applicable in a variety of practice settings.10,17

Many studies have demonstrated the benefits of NSAID use in the postoperative period with respect to decreasing opioid use and opioid-related side effects.3 Sedation, constipation, ileus, and respiratory depression are serious opioid-related side effects that can extend the recovery period and hospital stay.3,18

We chose a minimally invasive surgical technique for our ERAS pathway. Many systematic reviews and studies suggest minimally invasive approaches for lumbar microdiscectomies due to the associated benefits, including reductions in blood loss, pain, operation time, duration of the recovery period, hospital stay, and costs.19 According to our ERAS protocol, we conducted the development and early experience with an evidence-based ERAS pathway for minimally invasive lumbar microdiscectomy procedures. Minimally invasive techniques directly minimize the biochemical stress response, and the targeted hypotension and restricted intraoperative fluid administration of ERAS protocols minimize intraoperative blood loss. Advances in technology, many improvements in surgical specialties, and the minimally invasive techniques all decrease perioperative morbidity.

Wang et al. demonstrated the efficacy and reliability of an ERAS pathway by using a minimally invasive surgical technique for spinal fusions. Sedation with ketofol (combination of ketamine and propofol) was used instead of general endotracheal anesthesia. Tissue trauma was minimized with 8-mm incisions. A combination of endoscopic decompression, cage deployment prior to screw placement, and long-acting liposomal bupivacaine infiltrative anesthesia were performed without general endotracheal anesthesia. Similar to our results, the results of Wang and colleagues showed decreased operative time, blood loss, hospital length of stay, and cost of hospitalization in patients treated with an ERAS protocol.21

Grasu et al. conducted a retrospective cohort study of spine surgery in patients with metastatic tumors. They described the implementation of ERAS and compared 41 patients who participated in ERAS with 56 patients who underwent surgery before ERAS implementation. The ERAS group had better pain scores with less opioid consumption.5

In another study of ERAS in spine surgery, Wainwright et al. reported that ERAS intervention accelerated recovery and provided improved long-term outcomes in major spine surgeries.20 Mathiesen et al. studied multimodal pain control and found improved mobilization and less opioid consumption with this pain management after multilevel spine surgery.24

Although our study had a small sample size and our determination of patients’ readiness for discharge is somewhat subjective and was not easy to capture, we did find that the ERAS group had a significantly shorter length of hospital stay. This result can be explained by 2 factors: shorter operative time and better pain management.

We used institutional accounting data for cost analysis. Our results supported the evidence that ERAS not only provides preoperative benefits but also decreases healthcare costs. The current analysis included assessment of anesthetic and surgery costs and, as expected, ERAS was found to be cost-effective. Randomized controlled trials with the intention of evaluating all associated costs are needed to comprehensively assess the benefits of ERAS in spine surgeries.

Although this study was retrospective, the ERAS and pre-ERAS cohorts were similar in sample size, demographics, ASA classification, and surgery type, allowing for comparison between the groups. Given the short duration of data collection reported here, further initiatives are needed.

**Conclusions**

Our report shows that the adoption of a comprehensive ERAS program in spine surgery is beneficial and the program is simple to apply, but we believe that there is a need for international guidelines in order to standardize the comparisons for further improvements of the outcome and care of the patients undergoing spine surgeries.

**References**


3. Dunn LK, Durieux ME, Nemerut EC: Non-opioid analge-

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Naderi. Acquisition of data: Tarıkçı Kılıç. Analysis and interpretation of data: Tarıkçı Kılıç, Demirbilek. Critically revising the article: Naderi. Statistical analysis: Tarıkçı Kılıç.

Correspondence
Ebru Tarıkçı Kılıç: Ümraniye Training and Research Hospital, Ümraniye, İstanbul, Turkey. ebru.tarke@yahoo.com.